Young David

PCSA Pres. R&D buys 1,706 shares at $2.69; stock now -78.7% from $11.97 52-week high; 5-insider cluster buy pattern.

Young David, President of Research & Development, purchased 1,706 shares at $2.69 on 2026-04-30, expanding his holdings by 14.1% to 13.8K shares. This transaction occurred within a cluster of 5 insider buys over the past 14 days, suggesting coordinated interest at depressed valuations. The stock has collapsed -78.7% from its $11.97 52-week high and now trades at $2.55, -2.0% over 30 days and -15.0% over 90 days. Critically, Young's cross-ticker track record shows exceptional timing: 5 prior buys with avg 90d return +1765.7% and a 100% win rate, and at PCSA specifically, his prior 3 measurable buys were uniformly well-timed at the 90-day mark, posting +2212.9%, +2187.0%, and +1614.7% returns respectively. However, current fundamentals are severely distressed: the company reported $0.00 revenue in the latest quarter, a $-3.4M net loss, and a $7.0M market cap. The clustering activity combined with Young's proven track record of identifying value inflection points merits close monitoring, but the profound revenue collapse raises questions about whether historical patterns remain predictive in a company facing potential existential challenges.

PCSA President of R&D buys 1,545 shares at $2.97; 3 of 3 prior buys at this ticker hit +90d gains; 5 other insiders bought within 14 days.

Young David's purchase of 1,545 shares represents a 14.6% increase in his PCSA holdings, adding to a pattern of buying activity: he repurchased shares on 2026-03-31 (outcome not yet measurable) and achieved 90-day returns of +1614.7% and +2212.9% on his two prior 2024–2025 buys at this ticker. His same-ticker timing pattern shows 3 of 3 prior buys were well-timed at the 90-day mark. Concurrently, 5 other insiders have bought within the past 14 days, forming a cluster buy pattern. However, the company remains unprofitable (net income of $-3,436,573.00 for the latest full fiscal year), trades at a current price of $3.10 that is -74.1% from its 52-week high of $11.97, and generated $0.00 revenue in the latest quarter, presenting substantial financial headwinds that contextualize the multiple insider purchases.

David Young (R&D President) buys 1,810 PCSA shares at $2.54; adds 20.7% to holdings amid cluster buy by 8 other insiders within 14 days.

David Young, President of Research & Development, purchased 1,810 shares at $2.54, increasing his stake by 20.7% to 10,562 shares total. His prior three purchases at PCSA all generated triple-digit 90-day returns (643.6%, 2426.9%, 2226.6%), and his cross-ticker track record shows a 100% win rate across 90-day periods with an average 90-day return of +1765.7%. Most notably, this transaction occurs within a 14-day cluster window where 8 other insiders simultaneously bought shares, signaling coordinated confidence from the executive team. Against this backdrop, the company reported $0.00 revenue in its latest quarter, a net loss of $-3,436,573.00, and a $6.9M market cap; the stock is currently -78.3% below its 52-week high. The convergence of consistent insider buy success at this ticker, immediate cluster confirmation from peers, and deeply depressed valuation relative to recent history creates a high-conviction signal despite fundamental distress.

President of R&D David Young buys 124,500 PCSA shares at $0.80; stock -88.4% from 52-week high; cluster pattern detected with 3 other insiders.

David Young, President of Research & Development, purchased 124,500 shares at $0.80 on 2025-01-27, increasing his holdings by 153.9% to 205,405 shares total. This buy occurs as PCSA trades at $14.81, down 88.4% from its 52-week high of $127.50 and down 35.6% over the past 30 days. The company reported zero revenue in its latest quarter and a net loss of $3,384,703 over the most recent full fiscal year. Young's two prior purchases at PCSA (2024-02-06 and 2024-02-07) both generated strong 90-day returns of +2226.6% and +2426.9% respectively, representing a 2-for-2 well-timed buy pattern at this ticker. The transaction is part of a cluster buy pattern, with 3 other insiders also purchasing shares within the past 14 days, suggesting coordinated confidence among management despite the unprofitable fundamentals and severe recent price deterioration.